| Lion Hospice & Palliative Care, Llc 601 Second Street, Clarksdale, MS, 38614 | |
| (662) 621-1171 |
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| Name | Lion Hospice & Palliative Care, Llc |
|---|---|
| Location | 601 Second Street, Clarksdale, Mississippi |
| Hospice ID | 251672 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 130 |
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| NPI Number | 1376863209 |
| Organization Name | North Haven Hospice & Palliative Care, Llc |
| Address | 1696 South Colrado Street Greenville, Mississippi, 38701 |
| Phone Number | (662)822-5844 |
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| NPI Number | 1477873305 |
| Organization Name | Lion Hospice & Palliative Care, Llc |
| Address | 2001 Hospital Drive Clarksdale, Mississippi, 38614 |
| Phone Number | (662)822-5844 |
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| NPI Number | 1831411024 |
| Organization Name | Genesis Hospice Care, Llc |
| Address | 2001 Hospital Dr Clarksdale, Mississippi, 38614 |
| Phone Number | (662)621-1171 |
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| Home Health Aides | 2 |
| Counselors | 1 |
| Homemakers | 7 |
| Licensed Practical or Vocational Nurses | 4 |
| Medical Social Workers | 1 |
| Physicians | 2 |
| Registered Nurses | 3 |
| Other Personnel | 3 |
| Total Employees | 23 |
|---|
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| Others | 2 |
| Total Volunteers | 2 |
|---|
News Archive
Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.
"When it comes to getting aid right, an all-too-familiar problem seems to be balancing the priorities of rich governments with what communities actually want," AlertNet reports in an article examining an essay written by Oxford University researcher Devi Sridhar and published in PLOS Medicine.
Discovery Laboratories, Inc., announced today that, on November 30, 2010, the Company received a Staff Determination letter from The Nasdaq Stock Market indicating that the Company has not established compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on or prior to November 29, 2010.
Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
An unprecedented study of preterm birth suggests that only some of the problems previously associated with preterm birth are actually caused by preterm birth itself.
› Verified 7 days ago
| Lion Hospice & Palliative Care, Llc Location: 601 Second Street, Clarksdale, Mississippi, 38614 Phone: (662) 621-1171 |